Immunotherapy drug may extend cancer-free time after head and neck cancer relapse
NCT ID NCT02769520
First seen Jan 29, 2026 · Last updated May 16, 2026 · Updated 12 times
Summary
This study tests whether the immunotherapy drug pembrolizumab, given after salvage surgery, can help keep head and neck cancer from returning in people whose cancer has come back locally. About 27 adults with confirmed squamous cell carcinoma of the head and neck are participating. The main goal is to see how long they remain cancer-free after treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
UCSD Moores Cancer Center
La Jolla, California, 92093, United States
-
University of California Los Angeles
Torrance, California, 90505, United States
-
University of California San Francisco
San Francisco, California, 94115, United States
Conditions
Explore the condition pages connected to this study.